Developing Airglove V2 Technology for Peripheral Arterial Disease Healthcare (DATPADH)

**总部位于苏格兰汉密尔顿的绿十字医学公司（Green Cross Medico）向Innovate UK申请了快速启动创新资助，以协助开发其独特的、获得专利的Airglove外周动脉疾病（PAD）技术。该公司已经花了五年多的时间开发Airglove Arm，它可以提供热空气治疗，作为热血管扩张剂。Airglove的第一代用途是改善静脉注射困难（DIVA）插管。仅在英国，每年就有超过3200万次注射，近三分之一的人需要多次尝试。Airglove有助于DIVA插管，只需3分钟即可扩张静脉以改善通道，并用于许多临床领域，如肿瘤学，血液学，血液分离，输液，PET扫描，核医学，血浆交换治疗和放射学，在试验中证明首次插管成功率为87.5%。“Airglove帮助我们解决了一些非常困难的病例，有时我们不得不转移到中央静脉导管。”剑桥大学阿登布鲁克医院的护士/医生菲利普·斯塔瑟教授与我们密切合作，与我们合作，重新开发PAD技术。获得的赠款将帮助该公司开发用于PAD患者自我管理家庭治疗的Airglove Leg。全球有2亿人患有外周动脉疾病，这是由腿部动脉脂肪堆积引起的。它会导致腿部疼痛（间歇性跛行）和活动能力降低。有时PAD可发展为严重的肢体缺血，最坏的情况是在诊断后6个月内截肢，死亡率为20%。IUK Fast Start拨款将资助新一代国际兼容的Airglove设备的开发，该设备用于LEG使用电池组，一次性手套，定位该设备用于英国/国际使用。Airglove LEG将改善患者的预后和生活质量，包括他们的护理人员。它还将为临床医生提供一个有效的工具，在他们的医院信托没有监督运动疗法（SET）或患者由于行动不便而无法旅行的情况下，进行PAD的自我管理家庭治疗。Airglove将降低NHS和其他医疗保健付款人的成本，并有助于增加患者的流量，帮助解决NHS积压的问题，正如卫生部长所概述的那样，360亿英镑的投资“新的治疗、诊断和简化的手术方法，相信会让更多的患者得到快速、安全的治疗”。Airglove还将在英国创造额外的制造业、出口和就业机会。

**Public description**Green Cross Medico, based in Hamilton, Scotland, applied for a Fast Start Innovation grant from Innovate UK to assist with the development of its unique and patented Airglove technology for peripheral arterial disease (PAD). The company has spent over five years developing Airglove Arm, which delivers warm-air treatment to act as a thermo-vasodilator.The first generation use of Airglove was to improve Difficult Intravenous Access (DIVA) cannulation. In the UK alone, over 32M cannulations take place each year and nearly one third require more than one attempt. Airglove facilitates DIVA cannulation, taking just 3 minutes to dilate the vein for improved access and is used in many clinical areas such as oncology, haematology, apheresis, infusion, PET Scans, nuclear medicine, plasma exchange therapy and radiology with proven 87.5% 1st time cannulation success in trials."Airglove has helped out with some really difficult cases where we would sometimes have to move to central lines" Nurse/Practitioner at Addenbrooke's Hospital, CambridgeHaving worked closely with NHS Innovation South East we were approached by Professor Philip Stather to re-develop the technology for PAD. An awarded grant will assist the company to develop Airglove Leg for self-management home therapy of patients with PAD. 200M people globally suffer with PAD, which is caused by a build-up of fatty deposits their leg arteries. It can result in leg pain (intermittent claudication) and reduced mobility. Sometimes PAD can progress to critical limb ischaemia and, worst case scenario, leg amputation with a 20% mortality within 6 months of diagnosis.The IUK Fast Start grant will fund the development of a new generation of internationally-compatible Airglove device for the LEG use with battery pack, disposable gloves, positioning the device for UK/International use.Airglove LEG will improve patient outcomes and quality of life including their carers. It will also provide clinicians with an effective tool for the self-management home therapy of PAD if supervised exercise therapy (SET) is not available in their hospital trust or patients are not able to travel due to mobility.Airglove will reduce costs for the NHS and other healthcare payers plus help increase the flow-through of patients helping to tackle the NHS backlog as outlined in the Health Secretary £36billion investment of "New treatments and diagnostic and streamlined surgical methods believed to result in more patients being seen to quickly and safely". Airglove will also create additional manufacturing, exports and employment in the UK.